Valor202020212022202320242025TTMGastos comerciales, generales y administrativos105.33 M122.36 M152.85 M184.26 M280.32 M448.73 M448.73 MInvestigación y desarrollo114.76 M113.86 M130.99 M184.35 M246.89 M254.91 M254.91 MBeneficio operativo128.2 M124.48 M112.63 M107.28 M136.95 M44.8 M44.8 MTotal de ingresos no operativos———17.27 M24.54 M21.67 M21.67 MGastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses———17.27 M24.54 M21.67 M21.67 MIngresos/gastos extraordinarios———————Beneficio antes de impuestos131.6 M125.01 M116.19 M124.56 M161.49 M66.46 M66.46 MParticipación en los beneficios———————Impuestos25.59 M12.49 M14.77 M18.42 M20.28 M-33.19 M-33.19 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-148 K-10 K00———Beneficio neto antes de actividades interrumpidas106.01 M112.51 M101.42 M106.14 M141.21 M99.65 M99.65 MOperaciones suspendidas———————Beneficio neto106.01 M112.51 M101.42 M106.14 M141.21 M99.65 M99.65 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas106.01 M112.51 M101.29 M105.5 M139.73 M98.17 M98.17 MBeneficio básico por acción0.920.970.951.021.350.950.95Beneficio por acción diluido0.850.890.870.941.230.820.82Número medio de acciones ordinarias115.41 M115.65 M106.79 M103.56 M103.23 M103.86 M415.62 MAcciones diluidas124.19 M125.96 M115.97 M111.74 M113.48 M119.99 M479.73 MEBITDA128.73 M125.55 M113.42 M107.86 M137.75 M45.95 M45.95 MEBIT128.2 M124.48 M112.63 M107.28 M136.95 M44.8 M44.8 MCosto de los ingresos5.58 M5.28 M5.38 M6.48 M10.88 M12.98 M12.98 MOtros costes de producción———————Amortización y depreciación (flujo de caja)525 K1.07 M782 K577 K795 K1.15 M1.15 M
Corcept Therapeutics Incorporated
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.